Clinical Trial Update: A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy [Phase 1, Phase 2]

View source ↗

Summary

A safety surveillance study of human embryonic stem cell–derived retinal pigment epithelium cell therapy for age-related macular degeneration is ongoing in Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Human embryonic stem cell-derived retinal pigment epithelium cell therapy

Snippet

Sponsor: Astellas Institute for Regenerative Medicine | Conditions: Macular Degenerative Disease | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION